arGEN-X Enters Long-term Strategic Alliance with Shire in Therapeutic Antibodies

News   Jun 05, 2014

 
arGEN-X Enters Long-term Strategic Alliance with Shire in Therapeutic Antibodies
 
 
 

RELATED ARTICLES

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

‘Bad’ Antibodies Provide Crucial Protection Against Invading Microbes

News

In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.

READ MORE

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas

News

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE